[go: up one dir, main page]

MX9708854A - Terapia de genes para regulacion de celulas efectoras. - Google Patents

Terapia de genes para regulacion de celulas efectoras.

Info

Publication number
MX9708854A
MX9708854A MX9708854A MX9708854A MX9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A MX 9708854 A MX9708854 A MX 9708854A
Authority
MX
Mexico
Prior art keywords
nucleic acid
encoding nucleic
present
acid molecules
gene therapy
Prior art date
Application number
MX9708854A
Other languages
English (en)
Inventor
Steve W Dow
Robyn E Elmslie
Terence A Potter
Original Assignee
Nat Jewish Ct For Immunology A
Respiratory Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/446,918 external-priority patent/US5705151A/en
Application filed by Nat Jewish Ct For Immunology A, Respiratory Medicine filed Critical Nat Jewish Ct For Immunology A
Publication of MX9708854A publication Critical patent/MX9708854A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion provee una composicion terapéutica basada en ácido nucleico para tratar a un animal enfermo controlando la actividad de células efectoras, incluyendo células T, macrofagos, monocitos y/o células asesinas naturales en el animal. Las composiciones terapéuticas de la presente invencion incluyen moléculas de ácido nucleico que codifican superantígeno, ya sea en presencia o ausencia de una molécula de ácido nucleico que codifica citoquina y/o moléculas de ácido nucleico que codifican quimioquina, dependiendo de la enfermedad que se está tratando. La presente invencion también se refiere a un auxiliar para usarse con vacunas basadas en ácido nucleico. Composiciones auxiliares de la presente invencion incluyen un inmunogeno combinado con moléculas de ácido nucleico que codifican superantígeno, ya sea en presencia o ausencia de una molécula de ácido nucleico que codifica citoquina y/o moléculas de ácido nucleico que codifican quimioquina.
MX9708854A 1995-05-18 1997-11-17 Terapia de genes para regulacion de celulas efectoras. MX9708854A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/446,918 US5705151A (en) 1995-05-18 1995-05-18 Gene therapy for T cell regulation
US08/580,806 US5935568A (en) 1995-05-18 1995-12-29 Gene therapy for effector cell regulation

Publications (1)

Publication Number Publication Date
MX9708854A true MX9708854A (es) 1998-08-30

Family

ID=27034800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9708854A MX9708854A (es) 1995-05-18 1997-11-17 Terapia de genes para regulacion de celulas efectoras.

Country Status (8)

Country Link
US (1) US5935568A (es)
EP (1) EP0850071A4 (es)
JP (1) JPH11508762A (es)
KR (1) KR19990014875A (es)
AU (1) AU704012B2 (es)
CA (1) CA2221305A1 (es)
MX (1) MX9708854A (es)
WO (1) WO1996036366A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075119A (en) * 1997-04-07 2000-06-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome
US6713284B2 (en) 1997-06-25 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Bacterial superantigen vaccines
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
CA2296798A1 (en) * 1997-07-21 1999-02-04 Morten Soegaard Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents
US7795020B2 (en) 1998-01-14 2010-09-14 Morphogenesis, Inc. Tumor cell vaccines
US7348015B2 (en) 1998-01-14 2008-03-25 Morphogenesis, Inc. Antigen modified cancer cell vaccines for cancer therapy
WO1999036433A2 (en) * 1998-01-14 1999-07-22 Morphogenesis, Inc. Materials and methods for treating oncological disease
ATE281844T1 (de) * 1998-01-16 2004-11-15 Univ Johns Hopkins Orale verabreichung von nukleinsäure-impstoffen durch partikelkomplexe
BR9908267A (pt) * 1998-02-27 2000-10-24 Univ Pennsylvania Plasmìdeo, composição farmacêutica, processos para induzir uma resposta imunológica em um indivìduo contra um imunógeno, para imunizar um indivìduo contra uma infecção por vìrus de herpes simples e para tratar um indivìduo que tem uma doença autoimune, vacina recombinante, e, patógeno atenuado vivo
EP1071411B1 (en) * 1998-04-20 2007-03-14 Torrey Pines Institute For Molecular Studies Topical immunostimulation to induce langerhans cell migration
EP1073749B1 (en) * 1998-04-22 2006-01-11 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
US6919318B1 (en) 1998-04-22 2005-07-19 Chiron Corporation Enhancing immune responses to genetic immunization by using a chemokine
AU748565B2 (en) * 1998-06-23 2002-06-06 Board Of Trustees Of The Leland Stanford Junior University Adjuvant therapy
US20030022854A1 (en) * 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
EP1097212B1 (en) * 1998-07-10 2008-12-24 U.S. Medical Research Institute of Infectious Diseases Anthrax vaccine
AU762813B2 (en) * 1998-08-13 2003-07-03 Walter Reed Army Institute Of Research Bacterial superantigen vaccines
EP1127132A1 (en) * 1998-10-07 2001-08-29 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
US6562800B1 (en) * 1998-10-30 2003-05-13 University Of Southern California Use of immunopotentiating sequences for inducing immune response
EP1185627A2 (en) * 1999-06-01 2002-03-13 Cornell Research Foundation, Inc. Activation of dendritic cells to enhance immunity
US7361329B2 (en) * 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
DE60234193D1 (de) 2001-06-14 2009-12-10 Scripps Research Inst Stabilisierte faktor viii mit gentechnisch konstruierten disulfidbindungen
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
WO2003035106A1 (en) * 2001-10-24 2003-05-01 Chemocentryx Methods and compositions for inducing an immune response by co-administering a chemokine with an antigen
AU2003291402A1 (en) * 2002-11-07 2004-06-03 Beth Israel Deaconess Medical Center MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
EP1661911B8 (en) 2003-09-05 2013-02-13 The Chemo-Sero-Therapeutic Research Institute Protease-resistant modified seb and vaccine containing the same
EP2726089A2 (en) * 2012-02-08 2014-05-07 Premune AB Prevention of inflammatory disorders in domestic non-human mammals

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
US4994369A (en) * 1987-12-15 1991-02-19 The Board Of Trustees Of The Leland Stanford Jr. Univ. T-cell activation related gene
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DD295869A5 (de) * 1989-09-19 1991-11-14 �K�K@������������@�K�Kk�� Rekombinante polypeptide und peptide, diese codierende nucleinsaeuren und verwendung dieser polypeptide und peptide in der diagnose von tuberkulose
SE8903100D0 (sv) * 1989-09-20 1989-09-20 Pharmacia Ab New pharmaceutical agent
DE69133485T2 (de) * 1990-01-17 2006-06-22 Terman, David S., Pebble Beach Verwendung von Staphylococcus Enterotoxin Homologe für Krebs-Therapie
WO1993024136A1 (en) * 1991-01-17 1993-12-09 Terman David S Tumor killing effects of enterotoxins, superantigens, and related compounds
EP0499003A1 (en) * 1991-02-14 1992-08-19 N.V. Innogenetics S.A. Polypeptides and peptides, particularly recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypeptides and peptides in the diagnosis of tuberculosis
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU7177494A (en) * 1993-06-25 1995-01-17 Board Of Regents, The University Of Texas System Pore-forming and superantigen encoding toxin cassettes for gene therapy

Also Published As

Publication number Publication date
EP0850071A4 (en) 2005-05-25
WO1996036366A1 (en) 1996-11-21
US5935568A (en) 1999-08-10
AU704012B2 (en) 1999-04-01
AU5801696A (en) 1996-11-29
JPH11508762A (ja) 1999-08-03
EP0850071A1 (en) 1998-07-01
KR19990014875A (ko) 1999-02-25
CA2221305A1 (en) 1996-11-21

Similar Documents

Publication Publication Date Title
MX9708854A (es) Terapia de genes para regulacion de celulas efectoras.
CA2223433A1 (en) Ob protein compositions and methods
CY1119951T1 (el) Συνθεσεις για αυξηση δραστηριοτητας τελομερασης και αγωγη λοιμωξης hiv
IL160015A0 (en) Use of biologically active hiv-1 tat, fragments or derivatives thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
ATE281840T1 (de) Behandlung von diarrhoe
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
DE69635899D1 (de) Polypeptid, das die differenzierung unterdrueckt
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
AU6989094A (en) Compositions and methods for treating cancer and hyperproliferative disorders
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
EP0400958A3 (en) Live vaccines
NO960309L (no) Agonister og antagonister for humaninterleukin-10
Schluesener et al. Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides
CA2272407A1 (en) Method and compositions for stimulation of an immune response to a differentiation antigen stimulated by an altered differentiation antigen
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
WO2000045849A3 (en) Use of cationic lipids to generate anti-tumor immunity
EA200700656A1 (ru) Стабильные жидкие композиции плазмидной днк
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BR0317132A (pt) Métodos de diagnóstico e tratamento de doença pulmonar intersticial
WO2001024764A3 (en) Cell targeting compositions and methods of using the same
RU95110774A (ru) Олигонуклеотиды, терапевтические композиции, применение композиций

Legal Events

Date Code Title Description
FA Abandonment or withdrawal